The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) reported $61.5 million in net product revenue for fiscal Q4 2024 and $172.0 million for the entire year in its preliminary results.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 71 hedge fund portfolios held SpringWorks Therapeutics, Inc ...

Explore SpringWorks Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SWTX.

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025. Quiver AI Summary. SpringWorks Therapeutics, Inc. announced that it ...

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $54.36, for a ...